Experimental studies utilizing rodent models of biliary cirrhosis have demonstrated that PDE-5 inhibitors enhance sinusoidal blood flow and decrease hepatic vascular resistance by improving NO bioavailability [267]. Here, PDE5A is linked to biliary liver cirrhosis.